Two other glutamine transporters, SNAT1 and SNAT2, were induced to compensate for glutamine uptake.18,19 Therefore, targeting ASCT2, SNAT1 and SNAT2 together should be evaluated for their tumour suppression capability. The gene discussed is SLC38A2; the disease is neoplasm.